Disitamab Vedotin Shows Promise in HER2-Positive Breast Cancer with Liver Metastasis
• Disitamab Vedotin (DV) significantly improved progression-free survival (PFS) compared to Lapatinib plus Capecitabine in HER2-positive advanced breast cancer with liver metastasis.
• The Phase III study (RC48-C006) is the first global prospective, randomized trial demonstrating the efficacy of a HER2-targeting ADC in this patient population.
• DV demonstrated a manageable safety profile, consistent with previous experience, offering a potential new treatment option for previously treated patients.
• The Biologics License Application for Disitamab Vedotin has been accepted and granted priority review by China's National Medical Products Administration.
© Copyright 2025. All Rights Reserved by MedPath